NCT05633654: Phase 3: (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC
- CTD
- Dec 1, 2022
- 1 min read
Updated: 4 days ago
First Posted | 2022-11-21 |
Trial status | Recruiting |
Sponsor | Gilead Sciences |
Abstract Presentation | |
Peer-reviewed journal publication | |
Press Release | |
FDA | |
NCCN |
NCT05633654: Phase 3: (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC
(Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63))
Official Title: |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
Intervention / Treatment: |
Drug: Sacituzumab govitecan-hziy (SG) Drug: Pembrolizumab Drug: Capecitabine |
Other Study ID Numbers: |
GS-US-595-6184 2024-512279-10 ( Other Identifier ) (OTHER: European Medicines Agency) |
ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT05633654 |